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Problem Definition
Cardiovascular disease (CVD) remains the leading cause of 
death in the United States, responsible for 840,768 deaths in 
2016. From 2006 to 2016, the US death rate from 
Cardiovascular disease decreased by 18.6% and decreased by 
31.8% from coronary artery disease (CAD) specifically. This 
decrease in mortality has largely been driven by early detection 
and initiation of statin therapy. Atherosclerotic risk factors 
have been evaluated in multiple longitudinal studies. These 
studies have defined advancing age, male gender, 
hypertension, dyslipidemias, diabetes, cigarette smoking and 
family history as predictors of cardiac events. In addition to 
this, an underrecognized surrogate marker for CAD is coronary 
artery calcification (CAC). This should be considered 
diagnostic for CAD. In the PROVIDI study, using a 
qualitative scoring system for CAC, the authors found a 
stepwise increase in the likelihood of cardiovascular events 
with increasing CAC burden (four-fold increase in CV events in 
patients with severe CAC relative to patients without CAC). Yet 
despite this, CAC remains an under-recognized and under-
reported marker of CAD and an opportunity for improvement. 
Aims For Improvement
Overall aim: Improve diagnosis and management of CAD 
based on CT chest imaging.
• Improve diagnosis of silent CAD based on CT chest imaging: 
more patients who have findings of CAC on CT chest 
imaging will be diagnosed with CAD.
• Increase the number of appropriate statin prescriptions 
based on CAD findings on CT chest imaging. 
Intervention
Our proposed intervention has three components which will be 
implemented sequentially.
1. Standardize the reporting format for CAC on CT chest 
imaging by the Radiology Department.
2. Creation of best practice advisory for CAC CT findings in 
Epic. The goal is to alert the provider on the presence of 
CAC, and thus CAD, and to consider statin initiation.
3. Educate Jefferson primary care providers on new best 
practice advisory that will prompt them to have a 
discussion about the presence of CAD and risks and 
benefits of statin initiation. 
Initial Measurement and Results
Study population: For this project, we have selected a total 
of 194 patients aged ≥40 years who had an inpatient stay at 
TJUH between July of 2018 and June of 2019, did not have an 
existing diagnosis of CAD and had CT imaging of the chest for 
any indication.
Results: There was a higher prevalence of females in this 
study 57% compared to males 43%. The majority of the 
patients fell into the age range of 60-79 and were White. 
Among the patients with CAC on CT, 57% were not taking a 
statin. Among the patients with diagnosis of diabetes and CAC 
on CT, 33% were not taking a statin. 31% of patients with 
hyperlipidemia and CAD findings were not taking a statin. 
Among those who had severe CAC, 30% were not prescribed a 
statin. Among them only 1 patient (2%) was prescribed 
alternative cholesterol lowering medication (ezetimibe).  Only 
18% of patients who had CAC had CAD discussed in their chart. 
31% of patients who had evidence of CAD on CT had follow-up 
with cardiology. 48% of patients with CAC on CT had Jefferson 
providers as PCP. Among them, 51% had follow-up with PCP 
shortly after imaging and only 11% had CAD discussed during 
that visit. 
Next Steps
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Fig 1. Distribution and severity of atherosclerotic findings on CT chest imaging. 
Fig 2. Percent of patients with CAC on a statin based on severity . 
Fig 3. Statin and aspirin prescriptions among the patients with CAC findings. 
Fig 4. Summary of important findings based on initial analysis of study population. 
Fig 5. Percent of patients with CAC findings on CT who had an 
internal PCP, followed-up with their PCP shortly after imaging and 
had CAD discussed by PCP during that visit. 
